Serving hundreds of leading biopharmaceutical companies globally:

Generated: October 15, 2018

DrugPatentWatch Database Preview

Celgene Corp Company Profile

« Back to Dashboard

What is the competitive landscape for CELGENE CORP, and when can generic versions of CELGENE CORP drugs launch?

CELGENE CORP has two approved drugs.

There are fourteen US patents protecting CELGENE CORP drugs.

Summary for Celgene Corp

US Patents:	14
Tradenames:	2
Ingredients:	2
NDAs:	2
Drug Master File Entries:	4
Patent Litigation for Celgene Corp:	See patent lawsuits for Celgene Corp
PTAB Cases with Celgene Corp as patent owner:	See PTAB cases with Celgene Corp as patent owner

Drugs and US Patents for Celgene Corp

+ Get email alerts for changes to this table

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-001	Mar 21, 2014		RX	Yes	No		➤ Sign Up				➤ Sign Up
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-003	Mar 21, 2014		RX	Yes	Yes	7,893,101	➤ Sign Up	Y	Y		➤ Sign Up
Celgene Corp	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-001	Aug 1, 2017		RX	Yes	No	9,738,625	➤ Sign Up		Y		➤ Sign Up
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-001	Mar 21, 2014		RX	Yes	No	7,208,516	➤ Sign Up				➤ Sign Up
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-003	Mar 21, 2014		RX	Yes	Yes	6,020,358	➤ Sign Up	Y	Y		➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

Paragraph IV (Patent) Challenges for CELGENE CORP drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	10 mg, 20 mg and30 mg	➤ Subscribe	2018-03-22

International Patents for Celgene Corp Drugs

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Country	Document Number	Estimated Expiration
Argentina	097237	➤ Sign Up
Japan	5936521	➤ Sign Up
Spain	2278467	➤ Sign Up
Australia	1447200	➤ Sign Up
World Intellectual Property Organization (WIPO)	0025777	➤ Sign Up
Country	Document Number	Estimated Expiration

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo

Mallinckrodt

Argus Health

McKinsey

Harvard Business School

Federal Trade Commission

Deloitte

Merck

McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.